U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT06973161) titled 'ESPERANZA: T-DXd Pan-tumor ECA Study' on April 23.
Brief Summary: In DESTINY-Pan-Tumor [DP-02], DESTINY CRC02 [DC-02], and DESTINY-Lung01 [DL-01], T-Dxd demonstrated tumor response across a broad range of HER2-expressing solid tumors, particularly IHC3+ patients.
This study will use real-world data (RWD) to identify IHC3+ patients in the real world who received SoC and compare them with IHC3+ patients who received T-DXd in the referent trials. The tumors included are: non-small cell lung cancer [NSCLC], colorectal cancer [CRC], endometrial cancer, bladder cancer, epithelial ovarian cancer, cervical cancer, pancreatic cancer, biliary...